Yuxing Biotechnology

Yuxing Biotech is a synthetic biology company specializing in the development of tRNA-based therapeutics to treat genetic diseases caused by premature termination codons (PTCs). The company leverages a proprietary tRNA technology platform to engineer suppressor tRNAs that can read through nonsense mutations, potentially restoring the production of full-length, functional proteins. Based in China, Yuxing Biotech focuses on addressing high unmet medical needs in rare genetic disorders such as Duchenne muscular dystrophy and cystic fibrosis. The company has attracted significant venture capital investment from firms like Source Code Capital and IDG Capital to advance its pipeline through pre-clinical development. Yuxing Biotech operates research and development facilities in Suzhou and Shanghai, positioning itself as a leader in the emerging field of tRNA-mediated medicine.